Postoperative Adverse Events in Treatment-Naïve Patients With Oral Cavity SCC Receiving Neoadjuvant Pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Otolaryngology -- Head & Neck Surgery
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients
JAMA Otolaryngol Head Neck Surg 2022 Aug 25;[EPub Ahead of Print], AL Tang, T O'Neil, S McDermott, S Tripathi, R Tikhtman, JR Mark, Y Patil, M Tabangin, M Altaye, TM Wise-Draper, CA ZenderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.